BUY Aurobindo Pharma — Goldman Sachs, 07 Aug 2026

byGoldman SachsHorizon: NA (inferred 1 year)7 Aug 2026via CNBC Awaaz.

Entry₹1,580.1Inferred

Target₹1,750

Stop lossNot given

CMP₹1,653.12d ago

Active+4.62%+5.86%upside left 11 mo left

Follow Goldman Sachs for new calls(100% target hit, 12 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 9 other Long-term calls on AUROPHARMA

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 5:01 am IST

30 supporting11 neutral8 opposing

Supports the BUY call (30)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·4 Sept · 2d ago

Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD

NewsEt-Markets·31 Aug · 6d ago

Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus® in the US. This product is used to treat asthma and COPD.

NSE · Press Release·31 Aug · 6d ago

Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus in the US. This marks the first product from Aurobindo's inhalation pipeline to be commercialized in

BSE · Company Update·31 Aug · 6d ago

Aurobindo Pharma Share Price Gains As USFDA Concludes Inspection At Subsidiary Lannett's Unit

NewsNdtv-Profit·24 Aug · 2w ago

Neutral / worth noting (11)

Aurobindo Pharma Ltd's wholly owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly owned subsidiary named Ávogent Lifesciences Private Limited.

BSE · Company Update·1 Sept · 5d ago

Aurobindo Pharma’s API plant gets three US FDA observations after inspection

NewsCnbc-Tv18·28 Aug · 1w ago

Here's why these four pharma stocks are in focus today

NewsCnbc-Tv18·24 Aug · 2w ago

Weighs against the BUY call (8)

USFDA Issues Three Observations To Aurobindo Pharma Arm's Facility In Andhra

NewsNdtv-Profit·28 Aug · 1w ago

Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA

NewsLivemint·24 Aug · 2w ago

Aurobindo Pharma shares in focus after USFDA closes Raleigh unit inspection with 11 observations

NewsCnbc-Tv18·17 Aug · 3w ago

Aurobindo Pharma shares fall after USFDA issues warning letter to Eugia's Unit 1

NewsCnbc-Tv18·14 Aug · 3w ago

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·6 Aug · 1mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.